Los Angeles, CA, United States
Los Angeles, CA, United States

Time filter

Source Type

News Article | January 15, 2016
Site: www.fastcompany.com

One item in President Barack Obama's State of the Union address this week overshadowed all the others: the announcement of a massive "moonshot" effort, led by Vice President Joe Biden, to cure cancer. Such a bold proclamation naturally begets a few questions, and the government started answering them today in a call with reporters by the National Institutes of Health (NIH), which includes the National Cancer Institute (NCI). The biggest question: Why now? The short answer is that the science has progressed radically of late. "A coalescence of events has led to this being a moment where this kind of initiative is particularly compelling," said NIH director Francis S. Collins. "We do, after all, understand cancer at the molecular level in a way that we did not understand it a few decades ago." As the product of genetic mutations, each person's cancer is a bit different. The cost of a complete gene sequencing for a patient has dropped to about $1,000, so they can now be treated in a customized way, instead of just with the blunt instruments of chemotherapy and radiation that treat everyone's cancer the same. "We are also learning that it's maybe more important to know what mutations are in the cancer cell than what organ system it arises in because that will be the thing that guides us to the right cure," said Collins. Chemo and radiation may still play a role, he said, but in conjunction with genetically targeted treatments, such as chemicals that block certain malformed proteins and vaccines that get the patient's own immune system to target the cancer cells. "Immunotherapy…has emerged as one of the most exciting developments in cancer of all time," said Collins. This has led to dramatic successes, he said, mentioning President Carter's possible cure of melanoma that had spread to his brain. But immune therapies have not helped many other types of cancers, and getting them to work will be a big part of future research. The government is in a better position to do this now, said Douglas R. Lowy, NCI Acting Director, because Congress last month gave parent organization the NIH its biggest funding increase in more than 10 years (after a decade of keeping its budget essentially flat). The NIH/NCI seems to have emerged as the center of the government's cancer moonshot, and it's aiming to better coordinate work among government agencies as well as outside parties like universities. NIH can make sharing of data a requirement of any research grants it awards, said Collins. NCI will also roll out a cloud database to hold anonymized medical records for up to 50,000 cancer patients, so researchers can mine details like their genetic mutations. The conversation got a bit tense on the subject of private for-profit players, especially the Cancer MoonShot 2020 program by Patrick Soon-Shiong, founder and CEO of biotech firm NantWorks. The program was announced the morning before the State of The Union address at a press conference attended by senior officials from biotech and pharma firms as well as of medical centers including Beth Israel and Columbia University. Several of them had met with Biden, together with representatives from agencies like the NCI and Food and Drug Administration. "Dr. Soon-Shiong is obviously a highly regarded entrepreneur, very interested in this space," said Collins, "but the program he talked about…does not involve the NCI or the FDA in a partnership way." The original moonshot program took more than a dozen years to get to its target, and no one expects to cure cancer in the year that Biden and Obama have left in office. Their successors could well be Republicans, and the two parties have fought viciously over health care issues. This time might be different, though. Representative Fred Upton, who chairs the House Committee on Energy and Commerce, tweeted support for Obama's plan during the State of the Union address, and the two parties united on additional funding for NIH last month. House Democrats and Republicans also joined overwhelmingly in July to pass the 21st Century Cures Act, which boosts funding and lowers barriers for moonshot-style medical research. (It hasn't passed the Senate.) "This tradition of bi-partisan support for medical research is longstanding," said Collins. "Everyone is anxious to find answers for cancer."


ORLANDO, Fla.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today that it will be exhibiting its new suite of oncology solutions at booth #5561 and providing demos at the Interoperability Showcase floor at booth #9000 Hall F, during the HIMSS 2017 Annual Conference & Exhibition in Orlando, Florida. Recognized as one of the premiere healthcare industry conferences, HIMSS17 brings together healthcare professionals from across the globe. Throughout HIMSS 2017, NantHealth will showcase its extensive Oncology Suite aimed at improving the effectiveness and efficiency of specialty care through clinical and IT solutions. The solution takes a holistic approach to patient care via molecular profiling, precision medicine decision support, care coordination and outcomes measurement providing a continuous feedback loop which supports the goal of higher quality care at a reduced cost. The solutions also support the Centers for Medicare & Medicaid Services’ (CMS) Innovation Center’s Oncology Care Model (OCM) program. The goal of the OCM is to achieve better care, smarter spending and healthier people. To support this model, NantHealth’s portfolio of solutions provides oncologists with the tools necessary to ensure that 21st century treatments are deployed across the country. Among its suite of next-generation solutions is NantHealth’s latest rendition of the Vitality® Glowcap®, a medication adherence system that tracks, reminds and alerts patients to reinforce them to take their prescribed medication, which now utilizes Bluetooth Low Energy (BLE) 4.0 communications. As the pace of technology innovation in healthcare continues to gain momentum, connected care has become critical to improving the patient experience, as it ensures a seamless delivery of health IT services at the point of care. In addition to showcasing this latest connected care solution, NantHealth will also be exhibiting the following solutions at booth #5561: While at the Interoperability Showcase in kiosk #9000 Hall F, NantHealth will demonstrate joint use cases led by HealthShare Exchange of Southeastern PA with Independence Blue Cross, University of Pennsylvania, NextGen and Comcast called “On the Road to Cancer Care 2020” addressing how technology will impact the future of cancer treatment. NantHealth will also deliver a “Scheduled Surgery and Recovery” use case with several key industry stakeholders, which follows a patient from a scheduled surgery through recovery demonstrating how interoperability is present throughout the journey. Additional use cases being displayed include: “As we continue on the path toward advancing cancer care, we’re constantly thinking about the ecosystem of influence that will help us achieve this goal,” said Dr. Patrick Soon-Shiong, CEO and founder of NantHealth. “Whether its personalized medicine identified via GPS Cancer or enabling providers to have access to treatment intelligence databases, there are many components that are responsible for working together to find the ways we can fight this longstanding battle against cancer. Health IT certainly plays a major role in connecting payers, providers and patients and it is a necessity if we’re ever going to defeat this disease.” This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law. NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.


Techniques are provided that include identifying robust features within a training image. Training features are generated by applying a feature detection algorithm to the training image, each training feature having a training feature location within the training image. At least a portion of the training image is transformed into a transformed image in accordance with a predefined image transformation. Transform features are generated by applying the feature detection algorithm to the transformed image, each transform feature having a transform feature location within the transformed image. The training feature locations of the training features are mapped to corresponding training feature transformed locations within the transformed image in accordance with the predefined image transformation, and a robust feature set is compiled by selecting robust features, wherein each robust feature represents a training feature having a training feature transformed location proximal to a transform feature location of one of the transform features.


Patent
NantWorks and Nant Vision Inc. | Date: 2015-06-17

An activity recognition system is disclosed. A plurality of temporal features is generated from a digital representation of an observed activity using a feature detection algorithm. An observed activity graph comprising one or more clusters of temporal features generated from the digital representation is established, wherein each one of the one or more clusters of temporal features defines a node of the observed activity graph. At least one contextually relevant scoring technique is selected from similarity scoring techniques for known activity graphs, the at least one contextually relevant scoring technique being associated with activity ingestion metadata that satisfies device context criteria defined based on device contextual attributes of the digital representation, and a similarity activity score is calculated for the observed activity graph as a function of the at least one contextually relevant scoring technique, the similarity activity score being relative to at least one known activity graph.


Patent
Nant Vision Inc. and NantWorks | Date: 2014-05-12

Systems and methods of verifying the results of an initial image recognition process are presented. A verification engine can receive a set of candidate images corresponding to the results of an image recognition process performed on a captured query image. The verification engine can determine an appropriate verification technique to apply to the images of the candidate set, and classify, re-rank or otherwise re-organize the candidate set such that the best match from the candidate set is confirmed as a proper match.


Patent
Nant Vision Inc., NantWorks and NantMobile | Date: 2015-03-02

A system for analyzing scene traits in an object recognition ingestion ecosystem is presented. In some embodiment, a trait analysis engine analyzes a digital representation of a scene to derive one or more features. The features are compiled into sets of similar features with respect to a feature space. The engine attempts to discover which traits of the scene (e.g., temperature, lighting, gravity, etc.) can be used to distinguish the features for purposes of object recognition. When such distinguishing traits are found, an object recognition database is populated with object information, possibly indexed according to the similar features and their corresponding distinguishing traits.


Patent
NantWorks | Date: 2012-10-08

Medicinal container bags are presented. Bags can include openers capable of sealing an opening of the bag. Disclosed bags further comprise electronic assemblies configured to detect opening or closing events as the openers The assemblies can compile usage data based on opener movement, and then provide the data to remote monitoring systems.


Patent
NantWorks | Date: 2016-02-03

Medicinal container bags are presented. Bags can include openers capable of sealing an opening of the bag. Disclosed bags further comprise electronic assemblies configured to detect opening or closing events as the openers move along the rims of the bag opening. The assemblies can compile usage data based on opener movement, and then provide the data to remote monitoring systems.


CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that the company will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017, at 9:20 a.m. ET at the Boston Marriott Copley Place hotel. An audio-only webcast of the presentation will be available at www.NantHealth.com. Listeners are encouraged to visit the web site at least 10 minutes prior to the start of the presentation to register, download and install any necessary software. The presentation will be archived and accessible on the web site for at least 90 days. NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.


CULVER CITY, Calif. & SARASOTA, Fla.--(BUSINESS WIRE)--NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has expanded adoption of GPS Cancer, a comprehensive molecular profile, in Florida with the new Genomics Lab Licensing agreement with the state. The test is an advanced proteogenomics molecular analysis that helps oncologists guide a patient’s treatment strategy, including informing choice of standard chemotherapy. “By sequencing the entire genome, which consists of more than 20,000 genes and three billion base pairs and also performing protein expression with quantitative proteomics, the most actionable data about the biology of the tumor is available to the oncologist before treatment begins,” said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth. “The importance of having this information available is the ability for the treating physician to now know which drugs and chemotherapeutic agents have a higher probability of being effective or resistant based on the proteogenomic profile of the patient's tissue. Access to this level of data before a treatment decision is made was never available before and it is our hope that the GPS Cancer test will transcend our current ‘trial and error’ standards of care. By personalizing an informed decision through real world data, we can change cancer outcomes for the better." One of the oncologists who has benefitted from the availability and use of GPS Cancer in Florida is Dr. Steve Mamus, a Harvard trained molecular biologist, who has introduced the molecular profile to his practice at the Cancer Center of Sarasota-Manatee (CCSM), and has offered it to more than 100 patients since GPS Cancer’s commercial availability in June 2016. The Florida Genomics Lab Licensing agreement adds to the global community of healthcare providers, payers, and a Fortune 50 company that has committed to covering or using this comprehensive molecular profile. The GPS Cancer profile, which integrates quantitative proteomics with whole genome (DNA) and transcriptome (RNA) sequencing, is the only integrated comprehensive molecular test of its type conducted in CLIA-certified and CAP-accredited laboratories. It provides oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer provides key insights based on the unique biology of a patient’s tumor—from the DNA to the RNA to the protein. This rich information helps doctors build more effective treatment plans based on FDA-approved drugs and active clinical trials, while enabling cancer researchers to design new clinical trials that harness the potential of the immune system. "What’s so unique about GPS Cancer is that it can predict whether a particular cancer will respond to chemotherapy, targeted therapy or immunotherapy before a patient is treated,” said Steve Mamus, MD, Cancer Center of Sarasota-Manatee. “As a physician, it’s imperative that I’m able to do everything I can to improve that outcome on [my patients'] behalf. Since GPS Cancer is the most advanced test of its kind currently on the market, it empowers us to better identify and offer treatments for our patients. This approach is revolutionary for oncologists and a major initiative in striving towards personalized care.” To learn more about Dr. Mamus and specific use cases with his patients and others, please visit here. Cautionary Note Concerning Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law. About NantHealth, Inc. NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong. About GPS Cancer™ GPS Cancer™ is a comprehensive molecular profile available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with unprecedented insight into the molecular signature of each patient’s cancer to inform personalized treatment strategies. GPS Cancer profiling is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for the QUILT programs. GPS Cancer is the most unique and comprehensive test available on the market today; this is the first test that has transcended beyond the genome and crossed to the proteome. For more information, visit www.gpscancer.com.

Loading NantWorks collaborators
Loading NantWorks collaborators